Phase 2 Schizophrenia Trial, Recruiting NCT06021197 Sponsor: China Medical University Hospital Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT06021197
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with schizophrenia according to standard psychiatric diagnostic guidelines (DSM-5-TR).
  • People whose schizophrenia symptoms are in remission — meaning eight specific symptoms (such as hallucinations, delusions, and social withdrawal) have been rated as mild or below on a standard assessment scale for at least 6 months, and whose overall symptom score on that scale is 59 or lower at the start of the trial.
  • People who are in good physical health and whose routine blood test results are not considered medically significant.
  • People who have been taking the same dose of antipsychotic medication (not including clozapine) for at least 6 months, and who are able to keep that same dose unchanged for the full 12-week study period.
  • People with enough education to communicate clearly and complete the study assessments.
  • People who agree to take part and sign a written consent form.

Who may not be able to join:

  • People who have a diagnosis of intellectual disability or a substance use disorder (including alcohol) according to DSM-5-TR guidelines.
  • People with a history of epilepsy, significant head injury, or serious medical or neurological conditions (other than schizophrenia) that could affect the study.
  • People who are pregnant or breastfeeding.
  • People who would be unable to follow the study procedures as required.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886 4 22052121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
China Medical University Hospital
Registry
ClinicalTrials.gov
Start date
12 October 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change of cognitive function composite

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov